health information
Posts tagged Therapeutics
Aarkstore Enterprise – ribonucleic acid (RNA) therapeutics
02 months ago
by admin
in Gene Research
Aarkstore announce a new report “ribonucleic acid (RNA) Therapeutics – sturdy likely for Unmet Demands in Pharma-deal with”. By means of his huge collection of market place analysis
Summary
considerable prospective for Unmet Demands in Pharma, the insights into the unmet demands in the pharmaceutical and healthcare market segments and likely, in which RNA therapies are proving to be CAN-tackle – The leading business intelligence provider, has his most recent investigation ribonucleic acid (RNA) Therapeutics publishes beneficial. The pharmaceutical report delves deeply into the market prospective that RNA therapies to maintain in the future. In addition, it delivers insights into the R & D pipeline and the promising drugs. The research examines the present competitive scenario of the RNA therapeutics industry. Lastly br
This report was produced making use of data and details derived from proprietary databases, primary and secondary study and in-home evaluation by GBI science portals group of sector specialists.
Scope The scope of this report contains:
– Thorough market characterization which includes the assessment of market likely, the annual price of treatment and treatment method usage patterns
– Key technologies that have a considerable influence on the investigation and improvement of RNA therapeutics have created
– crucial elements that the RNA therapeutics industry prospective can drive
– Key risks and problems associated with various RNA therapies br – Competitive landscape of RNA therapeutics market. The main businesses in this report examined Antisense Pharma GmbH, Lorus Therapeutics, Isis Pharmaceuticals, Alfacell Corporation, Genta Incorporated, Atlantic Healthcare, Alnylam, OPKO, Oxford Biomedica, Dicerna Pharmaceuticals, Silence Therapeutics plc, Cequent Pharmaceuticals, Inc and Santaris Pharma.
– Crucial. M & A activities and licensing agreements that have taken location is produced amongst 2008 and 2009 in the RNA therapeutics market place
good reasons for acquiring the finished report, organization improvement and marketing executives in strategizing their item launches and assist venture capitalists aid to identify promising tiny and medium enterprises. It makes it possible for you
– creating efficient tactics for pipeline products by use of potential regions
Begin-In-licensing and out-licensing possibilities by identifying goods that fill gaps in the portfolio
– development of strategic initiatives by learning the crucial strategies of the top rated competitors
– Identify potential SME businesses that guarantee a lot
-retaining, strengthening R & D pipelines by identifying new target mechanisms that make only in the class molecules with far more efficiency and higher safety “can
For much more information, please pay a visit to:
/> Or mail us or contact press@aarkstore.com +919272852585
Global Non-small Cell Lung Cancer Therapeutics Market to 13300000000 $ to 2015, according to a new report by Global Industry Analysts
01 year ago
by admin
in Health Conditions
San Jose, California (openPR) 24 June 2009
Lung cancer is one of the most common cancers worldwide, which not only increases the mortality rates but also improving the financial burden on society. The worldwide market for therapies against cancer of the lung is driven by factors such as line extensions for existing products, introduction of innovative products and advances in biotechnology. Cytotoxic drugs such as cisplatin, carboplatin, docetaxel (Taxotere), paclitaxel and gemcitabine (Gemzar ®) continues to dominate the pharmaceutical market for lung cancer, although targeted therapies have begun to impact the market. The lack of data demonstrating the clinical efficacy of targeted drugs contributes to the further use of cytotoxic drugs for the treatment of lung cancer.
Tarceva should continue its dominance in the global market for treatments for lung cancer, while approvals for Avastin, Erbitux, Zactima and other new therapies are expected to offer growth opportunities. Although the patents of the three major chemotherapy drugs – Paraplatin (carboplatin) to expire, Taxotere (docetaxel) and Gemzar (gemcitabine) in 2012, the development of new drugs and therapies is expected to offset declining revenues.
United States and Europe together dominate the world of non-small cell lung cancer therapeutics market, as identified in the report of the search for new markets. The market for therapies for small cell lung cancer in the U.S. due to the introduction of new immune therapies and increased uptake of VEGF (vascular endothelial growth factor) inhibitors such as Avastin. In addition, the introduction of targeted drugs such as Erbitux and Zactima expected the market sales of non-small cell lung cancer therapy. The introduction of Pfizer ProMune for pre Stimuvax NSCLC and Merck Serono for stage III NSCLC is expected that the growth prospects improve in the short term.
Key players in
lung cancer overall market for therapies include AstraZeneca Plc, Bristol-Myers Squibb, Eli Lilly & Co., F. Hoffmann-La Roche AG, Genentech Inc., GlaxoSmithKline plc, Novartis Pharmaceuticals Corporation, OSI Pharmaceuticals Inc. . and Sanofi-Aventis, among others.
report, “Lung Cancer Therapeutics: A Global Strategic Business Report, entitled” announced by Global Industry Analysts, Inc., presented an overview of market trends, product introductions / innovations, and recent activities of the industry. The report analyzes market data and analysis for non-small cell lung cancer Therapeutics in the following regions – USA, Europe and the world.
For more details on this report on the study of the market, please visit – About Global Industry Analysts, Inc. Global, Inc. P
###
clear = “all”
Global Industry Analysts, Inc., (GIA) is a renowned publisher of off-market research in the trade. Founded in 1987, the company is recognized worldwide as one of the world’s largest market research publishers recognized. The company employs over 800 people worldwide and publishes more than 1,100 large-scale research reports each year. In addition, the company also offers thousands of research products including reports of small businesses, reports on market trends and industry reports include all major industries worldwide.
Industry analysts
Tel 408-528-9966
Fax 408-528-9977
email press (at) StrategyR (dot) com
>
Http://www.StrategyR.com/ website
small cell lung cancer
Earth Therapeutics Orange Eye Care Unit 1kit
01 year ago
by admin
in Health Care Services
Earth Therapeutics Orange Eye Care Unit 1kit
- Herba-gel beauty mask
- Rejuvenal-C orange eye pads (5 pair)
- Complete one-step solution for restoring and rejuvenating delicate skin
The Orange Eye Care Kit offers a refreshing oasis in the middle of the stress, pollution, and environmental factors which can take their toll on the eyes and the delicate skin surrounding the eyes. To revitalize tired eyes and to protect from the aging and damaging effects of free radicals and environmental exposure, try on the Rejuvenal-C Orange Eye Pads. Infused with real Orange extract, Vitamin C, and a beneficial blend of nutrients, these pre-moistened treatment pads cool and refresh on contact– offering a convenient, one-step solution for restoring and rejuvenating delicate skin around the eyes. Used regularly over time, these treatment pads help to renew skin, prevent cell damage, and may even help to visibly reduce the appearance of fine lines and wrinkles. After a relaxing treatment with the Rejuvenal-C Orange Eye Pads, try on the Herba-Gel Beauty Mask to put the finishing touches on your eye care regimen. The Herba-Gel Mask can be used either warm or cool to further soothe and invigorate tired, strained eyes. Eyes are pampered. Tired skin is nourished and nurtured. Puffiness and swelling are relieved. Dark circles are visibly diminished. Skin around the eyes will look and feel soft, smooth, and radiant Includes: ~Rejuvenal-C Orange Eye Pads (5 Pairs) ~Herba-gel Beauty Mask
List Price: $ 14.40
Price: $ 9.29
Zacks Analyst Blog Highlights: Vivus, Roche, Glaxo Smith Kline, Abbott and Therapeutics orexigenic
01 year ago
by admin
in Health Conditions
Zacks Analyst Blog Highlights: Vivus, Roche, GlaxoSmithKline, Abbott and Orexigen Therapeutics
Zacks Analyst Blog Highlights: Vivus, Roche, GlaxoSmithKline, Abbott and Orexigen Therapeutics
Read more on Zacks.com via Yahoo! Finance
Stem Cell Therapeutics Market
01 year ago
by admin
in Health Conditions
Stem Cell Therapeutics Market events
political and business leaders to announce changes to Stem Cell Therapeutics, in particular the expected evolution of President Barack Obama on the funding restrictions Federal stem cell research. The U.S. Congress also will clarify the preliminary research on stem cells. The dynamics in the two branches of American government, and scientific developments and competition on world markets heralds cheap for stem cell research. make a difference with their ability and a permanent source of cells that make up tissues and critical organs, stem cells have the potential for new regenerative therapies and as research tools for drug developers with new therapies to test in diseased cells. ( html http://www. bharatbook. com / Market-Reports Stem Cell Therapeutics Markets. html / a>)
While Companies have the opportunity to find outside the United States, President Bush “seven restrictions on research on embryonic stem cells in the United States limits the U.S. market. expected changes in U.S. policy on U.S. markets. For market watchers in the pharmaceutical industry is the question of what they have the potential and where the exits. Alison Sahoo has built our analyst models to determine the best and most likely case scenarios for the market of stem cell therapies in the years to come.
The report is divided projected revenues and volumes of proceedings stem cell technologies for these segments in the areas of disease: />
This report is the result of exclusive interviews with industry leaders on stem cells, a review of medical literature and social databases and government publications. As part of this global analysis of the research on stem cells, the following companies were profiled:
Aastrom Biosciences, Advanced Cell Technologies, Brainstorm Cell Therapeutics, Celegene, ES Cell International MEDISTER, Neostem, OPEX Therapeutics Osiris Therapeutics Plureon, Regenetech, Revivicor, Stem Cell Sciences, StemLifeLine, thermogenesis, VetCell
Bioscience Contact us at:
;
Bharat Book Bureau
Tel: +91 22 27578668 Fax
: +91 22 27579131 Email
www. bharatbook. Com
Blog: http://bharatbookresearch. blogspot. Com>
We are the aggregator of information from the first plan, facilitates and supports the information needs of business. With more than 115,000 reports, you can get instant access and an overview on studies in yo for market research, business planning / strategic planning by the latest information in the form of reports, journals, magazines and databases on various industries like automotive, oil and textiles to get gas, transportation, pharmaceuticals, energy, banking, finance, insurance, risk management, intelligence, areas of consumer and durable goods , chemical and ur interest. bharatbook Contact us at info +91 22 27578668 / 27579438 or by e-mail @. com or on our website www. bharatbook. Com>
New Report on Stem Cell Therapeutics Market in Visionshopsters
01 year ago
by admin
in Health Conditions
Events
politics and business to announce changes for Stem Cell Therapeutics, in particular the expected movement of President Barack Obama on the federal funding restrictions on stem cell research. The U.S. Congress also will clarify forward on stem cell research. The dynamics in the two branches of American government, and scientific developments and competition on world markets heralds cheap for stem cell research. visionshopsters http://www. visionshopsters. com/product/1636/Stem-Cell-Therapeutics-Markets. Html With the ability to differentiate and a permanent source of cells that make up tissues and critical organs, stem cells have potential for new regenerative therapies and as tools for drug discovery for developers to test new therapies in the diseased cells. During
companies are able to find outside the United States, President Bush has limited restrictions on seven years of research on embryonic stem cells in the United States, the U.S. market. expected changes in U.S. policy on U.S. markets. For market watchers in the pharmaceutical industry is the question of what they have the potential and where the exits. Kalorama Information has taken on this issue in stem cells Therapeutics Markets addressed. Kalorama analyst Alison Sahoo has built models to determine the best , and most likely scenarios to the market of stem cells in the years to come. This report is divided revenue projections and volume
pulmonary disease Arthritis Incontinence osteoporosis Diabetes <
p> Cancer , orthopedics / p> AD Burns (severe) ;
leukemia / p> Ths report is the result of exclusive interviews with industry leaders on stem cells, a review of medical literature and social, databases and government publications. As part of this global analysis of the research on stem cells, the following companies were profiled: Aastrom Biosciences Advanced Cell Technologies Brainstorm Cell Therapeutics ; Celegene Stem Cell Sciences StemLifeLine / p> VetCell Bioscience For more information and submit to purchase a copy please visit: Contact: Visionshopsters
http://www. visionshopsters. com/product/1636/Stem-Cell-Therapeutics-Markets. Html
emailId Description: Marketing @ visionshopsters.
com Website: www. visionshopsters. Com>
Global Therapeutics industry inflammatory bowel disease
01 year ago
by admin
in Health Conditions
Global Inflammatory Bowel Disease Therapeutics Industry
Reportlinker.com announces that a new market research report is available in its catalogue:
Read more on PR Newswire via Yahoo! Finance
New report on Stem Cell Therapeutics Markets has in Visionshopsters
01 year ago
by admin
in Health Conditions
political and business events to announce changes for Stem Cell Therapeutics, in particular the expected movement of President Barack Obama on federal funding restrictions on stem cell research raise. The U.S. Congress also has a desire to specify forward on stem cell research. The dynamics in both branches of American government, along with the scientific developments and the competition on world markets heralds good market for stem cell research. http://www. visionshopsters. com/product/1636/Stem-Cell-Therapeutics-Markets. html With their ability to differentiate and to an ongoing source of cells that make up critical tissues and organs, stem cells have the potential for new regenerative therapies and as new research tools for drug developers to new therapies to test in diseased cells. During
companies have the opportunity to find outside the U.S., President Bush has limited seven-year restrictions on embryonic stem cell research in the U.S., the U.S. market. should initiate changes in U.S. policy in U.S. markets. For market watchers in the pharmaceutical industry is the question of what potential they have and where to take them off the market. Kalorama Information has taken on this issue in the stem cells Therapeutics Markets addressed. Kalorama analyst Alison Sahoo has built models to determine the best, and most likely case scenarios for the therapeutic market for stem cells in the coming years. This report is divided projected revenue and procedure volume for the stem cell technologies for these segments in the areas of disease: Cardiovascular disease < p> lung disease Arthritis incontinence osteoporosis Diabetes <
p> Cancer Orthopedics infertility Alzheimer’s Burns (severe) ;
lupus Parkinson’s disease liver failure Multiple Sclerosis Critical limb ischemia Crohn’s disease sickle cell anemia Multiple myeloma
NH’s lymphoma
leukemia Ths report is the result of exclusive interviews with executives in the stem cell industry, a review of the medical and social literature, government databases and publications. As part of this comprehensive analysis of stem cell research markets, the following companies were profiled: Aastrom Biosciences Advanced Cell Technologies Brainstorm Cell Therapeutics Celegene ES Cell International MEDISTER Neostem ; Opexa Therapeutics Osiris Therapeutics Plureon Regenetech Revivicor < p> Stem Cell Sciences StemLifeLine thermogenesis VetCell Bioscience To know more and this report in order to buy a copy please visit: Contact: Visionshopsters
http://www. visionshopsters. com/product/1636/Stem-Cell-Therapeutics-Markets. html
emailId: Marketing @ visionshopsters.
com Website: www. visionshopsters. com
Plant-based vaccine factory to produce vaccines and therapeutics within weeks of outbreaks
01 year ago
by admin
in Health Conditions
Plant-based vaccine factory to produce vaccines and therapeutics within weeks of outbreaks
The Fraunhofer Center for Molecular Biotechnology in Newark, Delaware, the Fraunhofer Center for Manufacturing Innovation in Boston, Massachusetts, the Boston University College of Engineering, and the biopharmaceutical company iBio, Inc. in Newark, Delaware, announced today that they have developed a fully automated, scalable “factory” that uses natural (non-genetically-modified) green plants …
Read more on News-Medical-Net
Sandoz To Acquire Oriel Therapeutics, Gaining Rights To Portfolio Of Respiratory Products Targeting Asthma And COPD
01 year ago
by admin
in Health Conditions
Sandoz To Acquire Oriel Therapeutics, Gaining Rights To Portfolio Of Respiratory Products Targeting Asthma And COPD
Sandoz has signed a definitive agreement to acquire Oriel Therapeutics, a privately held US pharmaceuticals company, gaining exclusive rights to a portfolio of generic drug candidates and related technologies targeting medicines in the inhalable respiratory drug market. Terms of the deal were not disclosed.
Read more on PharmaceuticalOnline
